P152R Mutation Within MeCP2 Can Cause Loss of DNA-Binding Selectivity

AbstractMeCP2 is a protein highly expressed in the brain that participates in the genetic expression and RNA splicing regulation. MeCP2 binds preferably to methylated DNA and other nuclear corepressors to alter chromatin. MECP2 gene mutations can cause rett syndrome (RTT), a severe neurological disorder that affects around one in ten thousand girls. In this paper, Molecular Dynamics (MD) simulations were performed to scrutinize how the MeCP2 P152R mutation influences the protein binding to DNA. Also, the Umbrella Sampling technique was used to obtain the potential mean forces (PMFs) of both wild-type and mutated MeCP2 Methyl-CpG-binding domain (MBD) binding to both non-methylated and methylated DNA. P152R is a common missense mutation in MBD associated with RTT; however, there are no studies that explain how it causes protein dysfunction. The results from this study hypothesize that P152R mutation leads to MBD binding more strongly to DNA, while selectively decreasing binding affinity to methylated DNA. These provide an explanation for previous not conclusive experimental results regarding the mechanism of how this mutation affects the binding of the protein to DNA, and subsequently its effects on RTT. Furthermore, the results of this research-in-progress can be used as the basis for further investigations into the molecular basis of RTT and to potentially reveal a target for therapy in the future.
Source: Interdisciplinary Sciences, Computational Life Sciences - Category: Bioinformatics Source Type: research

Related Links:

Publication date: February 2020Source: Trends in Anaesthesia and Critical Care, Volume 30Author(s): Joana Veiga, Sara Alves, Marta Gonçalves, Helena Salgado
Source: Trends in Anaesthesia and Critical Care - Category: Anesthesiology Source Type: research
Condition:   Rett Syndrome Intervention:   Drug: Trofinetide Sponsor:   ACADIA Pharmaceuticals Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 15 February 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular Basis of DiseaseAuthor(s): Marine Brousseau, Juliette Nectoux, Benjamin Saintpierre, Nicolas Lebrun, Nicolas Cagnard, Brigitte Izac, Emmanuelle Olivier, Franck Letourneur, Thierry BienvenuAbstractWidespread random monoallelic gene expression (RMAE) effects influence about 10% of human genes. However, the mechanisms by which RME of autosomal genes is established and those by which it is maintained both remain open questions. Because the choice of allelic expression is randomly performed cell-by-cell, the RMAE mechanism...
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - Category: Molecular Biology Source Type: research
Publication date: Available online 12 February 2020Source: NeuroscienceAuthor(s): Merrick S. Fallah, James H. EubanksAbstractGenetic neurodevelopmental disorders that often include epilepsy as part of their phenotype are a heterogeneous and clinically challenging spectrum of disorders in children. Although seizures often contribute significantly to morbidity in these affected populations, the mechanisms of epileptogenesis in these conditions remain poorly understood. Different model systems have been developed to aid unraveling these mechanisms, which include a number of specific mutant mouse lines which genocopy specific ...
Source: Neuroscience - Category: Neuroscience Source Type: research
Amelia and Ruby Sampson, from Birmingham, have Rett syndrome. They may not make it to adulthood. Rett claimed the life of Coleen Rooney's sister Rosie McLoughin aged 14.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Conditions:   Rett Syndrome;   RTT Intervention:   Drug: GWP42003-P Sponsor:   GW Research Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We examined the merits and flaws of the Rett Syndrome Behavioural Questionnaire (RSBQ) as an outcome measure for clinical trials.
Source: Pediatric Neurology - Category: Neurology Authors: Tags: Research Paper Source Type: research
Conditions:   Rett Syndrome;   RTT Intervention:   Drug: GWP42003-P Sponsor:   GW Research Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Intellectual and Developmental Disabilities,Volume 58, Issue 1, Page 49-64, February 2020.
Source: Intellectual and Developmental Disabilities - Category: Disability Authors: Source Type: research
AbstractThe discovery and initial characterization 20  years ago of antinuclear autoantibodies (ANAs) presenting a dense fine speckled (DFS) nuclear pattern with strong staining of mitotic chromosomes, detected by indirect immunofluorescence assay in HEp-2 cells (HEp-2 IIFA test), has transformed our view on ANAs. Traditionally, ANAs have been conside red as reporters of abnormal immunological events associated with the onset and progression of systemic autoimmune rheumatic diseases (SARD), also called ANA-associated rheumatic diseases (AARD), as well as clinical biomarkers for the differential diagnosis of these dise...
Source: Autoimmunity Highlights - Category: Allergy & Immunology Source Type: research
More News: Bioinformatics | Brain | Genetics | Girls | Neurology | Rett Syndrome | Study